![Prof. Caroline Robert](https://vibconferences.be/sites/default/files/styles/speaker_overview_thumb/public/speaker-pictures/caroline_robert-300_0.jpg?itok=mfWqhfHf)
Na mediaan 57,7 maanden follow-up was de mediane OS 32,7 maanden in de gecombineerde pembrolizumab-groepen versus 15,9 maanden in de ipilimumab-groep (HR 0,73; p=0,00049). De mediane PFS was 8,4 maanden in de gecombineerde pembrolizumab-groepen versus 3,4 maanden in de ipilimumab-groep (HR 0,57; p<0,0001). Graad 3 of hoger adverse events werden gezien in 17% versus 20%, en serious AEs in 14% versus 18%. Eén patiënt overleed aan pembrolizumab-gerelateerde sepsis.
De onderzoekers concluderen dat na bijna vijf jaar follow-up pembrolizumab voor gevorderd melanoom superieur was over ipilimumab.
1.Robert C, Ribas A, Schachter J et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; epub ahead of print
Summary: Updated results of the multinational phase 3 study KEYNOTE-006 showed that after almost five years of follow-up pembrolizumab continued to show superiority over ipilimumab in terms of OS and PFS of patients with advanced melanoma.